

Date: 3rd June, 2026

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code: 533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APL LTD

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Appointment of Senior Management Personnel.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that Mr. Tushar Mehta is appointed as Head-R&D (API) (Senior Management Personnel) of the Company w.e.f. 3rd June, 2026.

The details as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026 is attached herewith as "Annexure-A".

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Alembic Pharmaceuticals Limited

Manisha Saraf
Company Secretary

Encl.: A/a.

ALEMBIC PHARMACEUTICALS LIMITED

Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) read with Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026:

Sr. No.	Particulars	Details of Change – Mr. Tushar Mehta
1.	Reason for change	Appointment
2	Date of appointment & term of appointment	3 rd June, 2026 Term of Appointment: Full-time employment
3	Brief profile (in case of appointment)	<p>Mr. Tushar Mehta has 24+ years of experience in API R&D.</p> <p>He has led 100+ API development programs, with over 45 successfully commercialized. In doing so, he built and directed R&D team of 200 scientists, filed multiple USDMFs, and steered projects through FDA and EMA regulations.</p> <p>His expertise includes small-molecule APIs, covering complex areas such as oncology and antiviral products, including Remdesivir and Molnupiravir, along with statins and other advanced APIs.</p> <p>Prior to joining Alembic, Mr. Tushar Mehta was SVP & Head – R&D (API) at Cadila Pharmaceuticals and was also associated with Piramal (O2h), Ami Life Sciences, and BDR Life Sciences in R&D leadership roles.</p>
4	Disclosure of relationships between directors	Not Applicable.

ALEMBIC PHARMACEUTICALS LIMITED